ASCO
-
healthGLP-1 Drugs Linked to Lower Breast Cancer Risk and Better Outcomes
Observational studies show GLP-1 meds like Ozempic may reduce breast cancer incidence by 30% and improve survival rates.
-
healthGLP-1 Drugs May Cut Breast Cancer Risk by 30%, Study Finds
GLP-1 medications like Ozempic and Mounjaro may reduce breast cancer risk by up to 30%, independent of weight loss, new research shows.
-
healthGLP-1 Drugs Like Ozempic Show Broad Cancer Protection Promise
Multiple studies at ASCO 2024 show GLP-1 drugs reduce cancer risk and improve outcomes across tumor types, with potential benefits tied to inflammation reduction and weight loss.
-
healthGlobal Cancer Care Faces 100 Million Worker Shortfall by 2050
A Lancet study projects a shortage of nearly 100 million cancer workers by 2050, with Africa and Asia hit hardest.
-
healthUltra-Low-Dose Immunotherapy Found to Extend Survival in Head and Neck Cancer
Phase III trial shows TMC-I regimen significantly improves survival over standard chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma.
-
healthNew Pancreatic Cancer Pill Shows Promise, 90% of Patients Respond in Early Trial
An experimental daily pill, daraxonrasib, shows a 90% disease control rate in advanced pancreatic cancer patients during early-stage clinical trials.